CHF 10,000 each for startups developing next-gen industrial robotics, a homemade food peer-to-peer app and, a platform to treat respiratory viruses infections
13.10.2020
Isochronic, Neia, and ViRelieve Therapeutics win Venture Kick's first stage of financial and entrepreneurial support. Their projects help industrials save time and money with next-generation "Continuous-Motion" robots, connect home-chefs and office-eaters via an app, and doctors treat respiratory syncytial virus infection, a leading cause of hospitalization in newborns, infants, and adults thanks a first-in-class stapled peptides targeting a different mechanism of action compared to traditional approaches.
7.jpg) |
 |
 Isochronic's CEO Melvin Haas, VP Software Albrecht Lindner, VP Hardware Pierre-Alain Buchs
|
|
 Neia's Team: From left to right standing: Tosca (Community Manager), Yanis (Customer Acquisition Manager), Blas (CEO), Janice (Operations Manager), Anouck (Culinary and Communication Manager)
From left to right at the bottom: Marie (Digital Marketing), Cédric (Artistic Director)
|
|
 ViRelieve therapeutics: Pr. Origène Nyanguile (Vice President of Preclinical Development), Dr Craig Shimasaki, MBA (Business Development Director) and Dr Ivan Ivanov (President & CEO) of ViRelieve Therapeutics.
|
|
Isochronic: The Future of Industrial Robotics
Isochronic's CEO Melvin Haas and VP Software Albrecht Lindner, both from the EPFL, together with VP Hardware Pierre-Alain Buchs develop the next generation of industrial robots based on the "Continuous Motion Robotics" (CMR) principle. Higher speeds, longer transport distances and improved precision are rendered possible at the same time by the innovative CMR robot concept. Capable of transporting multiple parts simultaneously, Isochronic's technology is based on a novel robot kinematic which greatly enhances the performance of pick & place operations in automated production lines, most notably industrial applications such as packaging-, part inspection- and palletizing operations within market segments such as electronics/semiconductors, medical/pharma, food processing as well as the precision- & watchmaking industries.
They will use the Venture Kick funds to co-develop a first mechanical prototype with a pilot customer, including the development of advanced motion control systems and path planning algorithms. isochronic.com
Neia: Homemade, well made.
Imagine being at your office and realising when lunch time comes that you don’t have anything tasty, nutritious or healthy to eat.You end up going to the supermarket or to the same corner take-away almost every day. You know that eating the wrong food is making you perform poorly in your personal and professional life, so sometimes you treat yourself to a restaurant, but that ends up being too expensive for your everyday.
Neia's team is committed to circular economy and to a socially responsible approach. Their community and ecosystem bring together Home Chefs and Eaters for you to have access to homemade, well made meals. Since their MVP release in Geneva back on May 15th in the middle of the COVID pandemic, more than 1’700 customers have registered at Neia and have traded almost 1’000 meals. Furthermore, Neia’s ecosystem of trust has managed to achieve a 55% second purchase ratio and has now been upgraded to an escalable V2 version, which is being released in Lausanne. Neia is a group of professionals who are together for the same reason: making well made, homemade meals available to every working professional across all major European cities. Within the founding team, employees and Board Members, Neia counts with an extensive list of serial entrepreneurs, top-rank school alumni, corporate executives and marketing experts.
After having successfully closed their Pre-Seed Round back in February 2020, Neia is now looking to achieve national coverage by February 2022 with more than 120k registered users and a total of 131k traded meals and to raise CHF 1.5mio to support this development. neia.app
Neia's team is committed to circular economy and to a socially responsible approach. Their community and ecosystem bring together Home Chefs and Eaters for you to have access to homemade, well made meals. Since their MVP release in Geneva back on May 15th in the middle of the COVID pandemic, more than 1’700 customers have registered at Neia and have traded almost 1’000 meals. Furthermore, Neia’s ecosystem of trust has managed to achieve a 55% second purchase ratio and has now been upgraded to an escalable V2 version, which is being released in Lausanne. Neia is a group of professionals who are together for the same reason: making well made, homemade meals available to every working professional across all major European cities. Within the founding team, employees and Board Members, Neia counts with an extensive list of serial entrepreneurs, top-rank school alumni, corporate executives and marketing experts.
After having successfully closed their Pre-Seed Round back in February 2020, Neia is now looking to achieve national coverage by February 2022 with more than 120k registered users and a total of 131k traded meals and to raise CHF 1.5mio to support this development. neia.app
ViRelieve Therapeutics: an innovative therapeutic platform to treat respiratory viral infections with a multi-billion dollar market opportunity
Respiratory Syncytial Virus (RSV) is the most common pathogen associated with respiratory conditions such as bronchiolitis, croup and pneumonia. It is a major cause for admission to hospital for newborns, infants and adults. It is estimated that 33.8M RSV infections occur every year in children under 5 years old from which more than 2M lead to hospital admissions and more than 200 000 deaths per year. As well RSV is a major cause of morbidity and mortality in the elderly. Currently, there are no good therapeutics on the market. Each year, the virus causes a huge economic burden in the western world because of the large number of infants that must be hospitalized in intensive care units. Globally 64M people/year look for RSV drugs that are not currently available and the total economic burden for health care system is about 5bn per year.
Respiratory Syncytial Virus (RSV) is the most common pathogen associated with respiratory conditions such as bronchiolitis, croup and pneumonia. It is a major cause for admission to hospital for newborns, infants and adults. It is estimated that 33.8M RSV infections occur every year in children under 5 years old from which more than 2M lead to hospital admissions and more than 200 000 deaths per year. As well RSV is a major cause of morbidity and mortality in the elderly. Currently, there are no good therapeutics on the market. Each year, the virus causes a huge economic burden in the western world because of the large number of infants that must be hospitalized in intensive care units. Globally 64M people/year look for RSV drugs that are not currently available and the total economic burden for health care system is about 5bn per year.
ViRelieve is a spin-off of the HES-SO Valais-Wallis co-founded by Dr Ivan Ivanov (President&CEO), Dr Craig Shimasaki, MBA (Business Development Director), and Pr Origène Nyanguile (Vice President of Preclinical Development) who is the main inventor of the assets. ViRelieve develops first-in-class peptides with great added value compared to small molecules and antibodies. Our broad vision is the development of a technology platform targeting several viruses in the same family (Parainfluenza, MetaPneumovirus, Ebola, Zika and Nipah).
The Venture Kick funds will be used for business development and intellectual property patent prosecutions. ViRelieve is in the process of raising seed capital and Venture Kick Phase I grant is well suited to support our fundraising process. The visibility Venture Kick provides to start-ups in the Switzerland ecosystem will help us accelerate our growth. virelieve.com